2024년 세계 바이오테크놀러지 시장 규모는 7,615억 달러에 달했습니다. 향후 IMARC Group은 2033년까지 시장 규모가 1조 3,159억 달러에 달하고, 2025-2033년 6.27%의 연평균 성장률(CAGR)을 보일 것으로 예측하고 있습니다. 맞춤형 의료 연구개발(R&D) 증가, 유전공학의 수많은 발전, 지속 가능한 농업에 대한 수요 증가 등이 시장 성장의 주요 요인으로 작용할 것으로 예측됩니다.
바이오테크놀러지은 혁신적인 제품과 기술을 개발하기 위해 생물, 세포, 생물 시스템을 활용하는 다학제적 분야입니다. 분자 및 세포 수준의 생물학적 과정과 생물을 활용하여 헬스케어, 농업, 환경 관리 등 산업을 가로지르는 다양한 과제를 해결합니다. 바이오테크놀러지에는 유전공학, 바이오의약품, 바이오인포매틱스, 합성생물학 등의 분야가 포함되며, 이 모든 분야는 새로운 솔루션의 창출, 기존 프로세스의 개선, 생명시스템에 대한 이해 증진을 목표로 합니다. 이 분야는 현대 의학, 지속 가능한 농업, 다양한 용도의 신소재 개발을 형성하는 데 중요한 역할을 하고 있습니다.
유전자 연구와 분자생물학에 대한 이해의 급속한 발전으로 유전자 편집, 개인 맞춤형 의료, 새로운 치료법 등의 분야에서 기술 혁신이 진행되면서 예측 기간 동안 시장 성장을 가속할 것으로 예측됩니다. 또한, 만성 질환의 유병률 증가와 표적 치료의 필요성이 바이오 의약품 및 정밀의료에 대한 수요를 증가시켜 시장 성장에 긍정적인 영향을 미치고 있습니다. 또한, 세계 인구 증가와 한정된 경작지로 인해 지속 가능한 농업 솔루션에 대한 수요가 증가함에 따라 작물 개량 및 바이오 농약에 대한 바이오테크놀러지 기술의 채택이 가속화되고 있습니다. 이와는 별도로, 바이오인포매틱스로 알려진 정보기술과 바이오테크놀러지의 융합은 연구개발을 위한 데이터 기반 통찰력을 강화하여 시장 성장을 가속하고 있습니다. 또한, 환경 지속가능성에 대한 관심이 높아짐에 따라 생물학적 치료 방법 및 바이오연료 시장 개척이 시장 성장에 기여하고 있습니다.
유전공학의 급속한 발전
획기적인 CRISPR-Cas9 기술로 대표되는 유전공학의 놀라운 발전은 바이오테크놀러지 시장의 주요 촉진제입니다. 이 기술은 과학자들이 생물체 내의 유전자를 정확하게 변형할 수 있게 하여 의료, 농업, 산업 공정에 적용할 수 있는 전례 없는 가능성을 제시하고 있습니다. 의료 분야에서 유전공학은 유전성 질환과 암에 대한 혁신적인 유전자 치료법 개발을 촉진하고 개인 맞춤형 치료의 유망한 경로를 제공합니다. 또한, 인슐린이나 효소와 같은 귀중한 화합물 생산을 위해 미생물을 공학적으로 개량하는 능력은 제약 및 산업 제조에 변화를 가져왔습니다.
개인 맞춤형 의료와 치료제에 대한 수요 증가
개인의 유전적 체질에 맞춘 맞춤의료의 개념은 바이오테크놀러지 시장에서 지지를 받고 있습니다. 유전체 염기서열 분석 기술의 발전으로 개인의 유전 암호를 분석하여 질병과 관련된 유전자 변이를 파악할 수 있게 되었습니다. 이를 통해 환자 고유의 유전적 특징에 대응하는 표적 치료제가 개발되어 치료 효과의 향상과 부작용의 감소가 기대되고 있습니다. 바이오테크놀러지는 단클론 항체나 유전자 치료제 등 바이오 의약품의 제조를 가능하게 하여 개인맞춤의료의 원칙에 부합하고 있습니다. 또한, 유전자 마커에 기반한 진단은 질병의 조기 발견과 예후 예측을 가능하게 하고, 보다 정확하고 개인화된 접근 방식으로 의료를 재구성할 수 있습니다.
지속 가능한 농업 솔루션에 대한 수요 증가
세계 식량 수요 증가는 환경 문제 및 지속 가능한 농업 관행의 필요성과 함께 농업에서 바이오테크놀러지 솔루션의 채택을 촉진하고 있습니다. 수확량, 해충 저항성, 영양가를 높이기 위한 유전자 변형 작물(GMO)은 바이오테크놀러지이 농업에 미치는 영향의 한 예입니다. 자연계에 존재하는 생물에서 유래한 바이오 농약은 환경에 미치는 영향이 적어 기존 화학농약보다 선호되고 있습니다. 바이오테크놀러지은 식물의 형질을 최적화하고, 기후 변화에 대한 작물의 복원력을 향상시키며, 영양 효율을 높이는 도구를 제공하여 식량 안보와 자원의 지속가능성에 기여하고 있습니다. 이 동인은 생태학적 발자국을 최소화하면서 농업 분야의 시급한 과제를 해결하는 데 있어 바이오테크놀러지의 중요한 역할을 반영하고 있습니다.
The global biotechnology market size reached USD 761.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 1,315.9 Billion by 2033, exhibiting a growth rate (CAGR) of 6.27% during 2025-2033. The increasing research and development (R&D) in personalized medicine, numerous advancements in genetic engineering, and escalating demand for sustainable agriculture are some of the major factors propelling the market.
Biotechnology is a multidisciplinary field that encompasses the use of living organisms, cells, and biological systems to develop innovative products and technologies. It involves harnessing biological processes and organisms at the molecular and cellular level to address various challenges across industries, such as healthcare, agriculture, and environmental management. Biotechnology includes areas like genetic engineering, biopharmaceuticals, bioinformatics, and synthetic biology, all aimed at creating new solutions, improving existing processes, and advancing our understanding of living systems. This field plays a crucial role in shaping modern medicine, sustainable agriculture, and the development of novel materials for diverse applications.
The rising innovation in areas, including gene editing, personalized medicine, and novel therapies, due to rapid advancements in genetic research and the understanding of molecular biology, will stimulate the market growth during the forecast period. Moreover, the increasing prevalence of chronic diseases and the need for targeted treatments have augmented the demand for biopharmaceuticals and precision medicine, thus positively influencing the market growth. Additionally, the heightening demand for sustainable agricultural solutions owing to the expanding global population and limited arable land has accelerated the adoption of biotechnological techniques in crop improvement and biopesticides. Apart from this, the convergence of biotechnology with information technology, known as bioinformatics, that enhances data-driven insights for research and development is propelling the market growth. Furthermore, the development of bioremediation methods and biofuels on account of the escalating focus on environmental sustainability is contributing to market growth.
Rapid advancements in genetic engineering
The remarkable progress in genetic engineering, prominently exemplified by the revolutionary CRISPR-Cas9 technology, represents a primary driver in the biotechnology market. This technique allows scientists to precisely modify genes within organisms, presenting unprecedented potential for applications in medicine, agriculture, and industrial processes. In healthcare, genetic engineering facilitates the development of innovative gene therapies for genetic disorders and cancers, offering promising avenues for personalized treatments. Moreover, the ability to engineer microbes for the production of valuable compounds like insulin and enzymes has transformed pharmaceutical and industrial manufacturing.
Increasing demand for personalized medicine and therapeutics
The concept of personalized medicine, tailored to an individual's genetic makeup, is gaining traction in the biotechnology market. Advancements in genomic sequencing technologies have made it possible to analyze an individual's genetic code and identify genetic variations linked to diseases. This has led to the development of targeted therapies that address the unique genetic characteristics of patients, enhancing treatment efficacy and reducing adverse effects. Biotechnology enables the production of biopharmaceuticals such as monoclonal antibodies and gene therapies, aligning with the principles of personalized medicine. Additionally, diagnostics based on genetic markers allow for early disease detection and prognosis, reshaping healthcare practices toward more precise and individualized approaches.
Rising need for sustainable agriculture solutions
The increasing global demand for food, coupled with environmental concerns and the need for sustainable agricultural practices, fuels the adoption of biotechnological solutions in farming. Genetically modified crops (GMOs) engineered for enhanced yield, pest resistance, and nutritional content are examples of biotechnology's influence on agriculture. Biopesticides derived from naturally occurring organisms are gaining preference over traditional chemical pesticides owing to their reduced environmental impact. Biotechnology offers tools to optimize plant traits, improve crop resilience to climate change, and increase nutrient efficiency, contributing to food security and resource sustainability. This driver reflects the critical role of biotechnology in addressing pressing challenges within the agriculture sector while minimizing ecological footprints.
Instruments form the foundation of advanced research and diagnostics, enabling precise analysis and experimentation. Reagents are essential components that fuel experimental processes, facilitating accurate results and breakthroughs. Software plays a pivotal role, providing data analysis, visualization, and integration solutions, enhancing efficiency and accuracy in biotechnological endeavors. Services encompass consulting, training, and technical support, nurturing collaboration and aiding in the effective utilization of tools.
Furthermore, these components synergistically push the boundaries of biotechnology, fostering innovation and driving advancements that impact diverse sectors such as healthcare, agriculture, and environmental sciences. As the industry evolves, the strategic interplay of instruments, reagents, software, and services continues to shape the trajectory of biotechnology, fueling growth, discovery, and progress.
Nanobiotechnology integrates nanoscale materials with biological systems, revolutionizing drug delivery, diagnostics, and therapies. Tissue engineering and regeneration pioneers novel approaches for creating functional tissues, addressing organ shortages and medical needs. DNA sequencing enables comprehensive genomic analysis, guiding personalized medicine and disease understanding. Cell-based assays provide insights into cellular behavior, supporting drug development and toxicity testing. Fermentation is a cornerstone for bioprocessing, producing biofuels, pharmaceuticals, and enzymes. PCR Technology amplifies DNA, underpinning diagnostics and genetic research.
Chromatography separates biomolecules with precision, crucial in drug purification and analytical processes. These intertwined advancements drive the market's progress, fostering innovation and solutions across healthcare, agriculture, and environmental sectors.
Healthcare dominates the market
Healthcare serves as a pivotal driving force behind the biotechnology market, catalyzing innovations that transform patient care and medical practices. Biotechnology solutions play a vital role in diagnostics, treatment development, and personalized medicine. From advanced DNA sequencing enabling precise disease identification to biopharmaceuticals revolutionizing treatment modalities, the synergy between healthcare and biotechnology yields breakthrough therapies, improved patient outcomes, and enhanced disease management.
As healthcare and biotechnology intertwine, novel discoveries in areas such as gene editing, synthetic biology, and biomarker development further propelling the market growth. The biotechnology sector's continual evolution addresses current medical challenges and paves the way for future advancements, shaping the landscape of healthcare delivery and underscoring its significance as a critical driver of progress within the biotechnology domain.
North America exhibits a clear dominance in the market
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America held the biggest share in the market since the region boasts a robust ecosystem of research, innovation, and industry collaboration. The region's strong investment in research and development (R&D), coupled with its well-established regulatory frameworks, fosters an environment conducive to biotechnological breakthroughs. Various leading universities, research institutions, and biotech companies converge to push the boundaries of scientific discovery and technological advancements.
Furthermore, the rising emphasis of the North America region on entrepreneurship and venture capital further accelerates the commercialization of novel biotech solutions. With a history of pioneering achievements in areas such as genomics, pharmaceuticals, and medical devices, North America's influential role continues to shape the global biotechnology landscape, catalyzing growth, fostering innovation, and driving positive societal and economic impacts.
Key players in the biotechnology market have introduced groundbreaking innovations. Leading biopharmaceutical companies are developing mRNA-based vaccines that demonstrated remarkable efficacy in pandemic response. Additionally, advancements in CRISPR-based gene editing techniques have enabled precise and efficient modifications in various organisms, promising transformative applications in genetic therapies and modified crops. Furthermore, the integration of artificial intelligence (AI) and machine learning (ML) in drug discovery and development processes is accelerating the identification of potential drug candidates. These innovations reflect the industry's commitment to addressing global challenges, ranging from disease outbreaks to food security, through cutting-edge biotechnological solutions with the potential to reshape medical treatments, agriculture practices, and industrial processes. We also expect the market to witness new entrants, consolidation of portfolios, and an increase in strategic partnerships and collaborations among vendors to drive healthy competition within the domain during the forecast period.
In May 2022, F. Hoffmann-La Roche Ltd, a leading healthcare enterprise headquartered in Switzerland, introduced the innovative breast cancer antibody cocktail drug, PHESGO, to the Indian market. This breakthrough offering comes with a compelling advantage, as it is not only priced at a remarkable 20% lower than existing therapies but also offers a more streamlined and convenient administration process. It specifically targets HER-2 positive breast cancer, a challenging and prevalent subtype, while holding the distinction of being sanctioned for both early and advanced stages, including metastatic cases.
In January 2021, Novartis AG, a renowned pharmaceutical leader, entered into a strategic collaboration with Alnylam, a pioneering biotechnology company specializing in RNA interference (RNAi) technology. This innovative partnership aims to harness Alnylam's cutting-edge small interfering RNA (siRNA) technology to pave the way for a revolutionary targeted therapy. The focus of this collaboration centers on restoring optimal liver function, a critical aspect in numerous medical conditions.
In Jan 2023, Pfizer Inc., a global leader in biopharmaceuticals, collaborated with Gero, an avant-garde biotechnology company renowned for its advanced technology platform. This strategic research collaboration marks a convergence of expertise and technology, aiming to unlock new insights into the complex realm of fibrotic diseases. By harnessing Pfizer's extensive domain knowledge and Gero's state-of-the-art machine-learning capabilities, the partnership endeavors to chart unexplored territories in the understanding of genes and pathways linked to fibrosis - a group of disorders characterized by tissue scarring and dysfunction.